Indian Immunologicals

What Indian Immunologicals does

Indian Immunologicals Limited (IIL) is a Hyderabad-based vaccine manufacturer and wholly-owned subsidiary of the National Dairy Development Board (NDDB), a statutory body of the Government of India. Founded in 1982 and operating with 1,001–5,000 employees, the company is described as the market leader in veterinary and human biologicals in India. Its product portfolio spans both human and veterinary vaccines, built on inactivated vaccine platforms with recombinant and adjuvant formulations at the technology core.

Human vaccines include the Abhayrab anti-rabies franchise, with a 22-year market history and mandatory Central Drugs Laboratory testing, an improved Kyasanur Forest Disease (KFD) vaccine candidate developed with ICMR-National Institute of Virology and currently in Phase I human trials (doses administered 28 days apart), and a Hepatitis A vaccine. Veterinary offerings center on livestock vaccines including Foot and Mouth Disease products, in which IIL is recognized as a key global competitor alongside Merial/Boehringer Ingelheim, Zoetis, and MSD Animal Health. A six-in-one pediatric vaccine candidate was rejected by CDSCO for human trials. All India-supplied human vaccines pass through mandatory Central Drugs Laboratory testing.

Revenue is generated primarily through government procurement tenders (state livestock vaccination programs), healthcare distribution networks for human vaccines, and export of veterinary biologics. The go-to-market is institutional rather than consumer-direct, with notable customers including the Chhattisgarh government and CSR partnerships such as the Kerala Agricultural University dog welfare programme. Distribution is single-country domestic for human and most livestock supply, with a separate international channel for veterinary vaccines. As an NDDB subsidiary, IIL operates under the One Health framework, aligning animal and human health objectives with India's agricultural and public-health priorities.

Name

Indian Immunologicals

Legal name

Indian Immunologicals Limited

Website

https://indimmune.com

Company type

Private

Founded year

1982

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Indian Immunologicals Limited is a Hyderabad-based vaccine manufacturer and wholly-owned NDDB subsidiary producing human and veterinary vaccines — including the Abhayrab anti-rabies franchise and livestock vaccines — for Indian state governments, healthcare systems, and international veterinary biologics markets.

Ownership category

akta.pro rank

Product category

Human and Veterinary Vaccines

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Veterinary Vaccines (Biologics) (HLAMAEAL)

akta.pro secondary industries

Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH), Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM), Vaccine Programs & Tendering (Government/NGO, Eradication Campaigns) (HLAMAKAO)

Keywords

• Veterinary vaccines
• Human vaccines
• Vaccine manufacturing
• Biological products
• Livestock immunization

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales

Revenue model

1. Livestock Vaccines: Supply of livestock vaccines to state governments and agricultural sectors, including procurement by Chhattisgarh government to boost agricultural productivity.
2. Human Vaccines: Sale of human anti-rabies vaccine (Abhayrab) and other human vaccines through healthcare distribution networks and government immunization programs.
3. Veterinary Biologics Export: Export and supply of veterinary vaccines including Foot and Mouth Disease vaccines, positioning Indian Immunologicals among key global market players.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Indian Immunologicals Limited manufactures and supplies vaccines for both human and veterinary use, including the Abhayrab anti-rabies vaccine, Foot and Mouth Disease livestock vaccines, Hepatitis A vaccine, and a Kyasanur Forest Disease vaccine candidate. The company produces vaccines using inactivated, recombinant, and adjuvanted platform technologies, distributing them to state governments, agricultural departments, and healthcare systems across India and selected international markets. It operates as a multi-product vaccine manufacturer under the One Health framework, addressing human and animal health needs.

Product overview

Indian Immunologicals Limited (IIL) is a subsidiary of the National Dairy Development Board and a major Indian pharmaceutical/biotechnology company specializing in vaccine development and manufacturing. The company operates as a multi-product organization producing both human and veterinary vaccines. Its human vaccine portfolio includes Abhayrab (anti-rabies vaccine with 22-year market presence), the Kyasanur Forest Disease vaccine candidate currently in clinical trials, and Hepatitis A vaccine. IIL also manufactures a rejected six-in-one pediatric vaccine candidate. On the veterinary side, IIL produces livestock vaccines including Foot and Mouth Disease vaccines, and Chhattisgarh has authorized procurement of its livestock vaccines. All human vaccines undergo mandatory Central Drugs Laboratory testing and quality standards. IIL operates under the One Health framework and has formed strategic partnerships for biotech innovation.

Differentiator

Problem solved

Functional benefit

Brands

• Abhayrab: Human anti-rabies vaccine manufactured by Indian Immunologicals Limited, with a 22-year production history.

Products and services

• Abhayrab Human Anti-Rabies Vaccine Human anti-rabies vaccine sold to healthcare systems, hospitals, and government immunization programs in India and abroad.
• Kyasanur Forest Disease (KFD) Vaccine Candidate Two-dose, adjuvanted, inactivated vaccine against Kyasanur Forest Disease, a tick-borne viral hemorrhagic fever endemic to parts of Western Ghats, currently in Phase I human clinical trials.
• Hepatitis A Vaccine Human vaccine for Hepatitis A, marketed alongside global players such as GSK and Sanofi.
• Foot and Mouth Disease Vaccines Livestock vaccines for prevention of Foot and Mouth Disease, marketed to government agriculture departments and exported through international veterinary vaccine channels.
• Livestock Vaccines Range of livestock vaccines supplied to state governments and agricultural sectors, including procurement by the Chhattisgarh government for agricultural productivity.
• Six-in-One Pediatric Vaccine (Candidate) Pediatric combination vaccine candidate; currently not approved as CDSCO rejected human trials citing safety, containment, and WHO Poliovirus Containment Certification concerns.

Quantifiable outcome

• Increased dog sterilisation coverage from 34% to 70-80% through CSR programme

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Kerala Agricultural UniversityminorStrategic or Co-development Partner · 19 May 2026CSR partnership for dog welfare programme at College of Agriculture Vellayanan campus. The initiative sterilized 23 community dogs with support from 22 student volunteers, increasing sterilisation coverage from 34% to between 70% and 80% as part of the global 'Zero by 2030' goal.
• National Dairy Development Board (NDDB)coreOthers · 24 April 2026Indian Immunologicals Limited is a subsidiary of the National Dairy Development Board. NDDB Chairman Meenesh Shah's tenure was extended, and he heads several NDDB subsidiaries including IIL.
• ASPIRE-BioNEST (University of Hyderabad)coreStrategic or Co-development Partner · 27 March 2026Strategic MoU signed to advance biotech innovation under the One Health framework, supporting startups across therapies, diagnostics, medical devices, and allied technologies. The partnership enables co-development, validation, technology transfer, and market access, with IIL providing technical mentorship, domain expertise, and access to advanced process development and analytical facilities including capabilities relevant to viral and bacterial vaccine development.
• ICMR-National Institute of VirologycoreStrategic or Co-development Partner · 8 February 2026Collaboration for development of improved Kyasanur Forest Disease (KFD) vaccine. The candidate vaccine is a two-dose, adjuvanted, inactivated vaccine with doses administered 28 days apart, developed under the Department of Health Research to overcome limitations of the existing KFD vaccine.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• MSD Animal Health (Merck): Competitor in the FMD vaccine market alongside IIL, with broad veterinary vaccines and biologics portfolio targeting livestock producers globally.
• Zoetis: World's largest animal health company directly competing with IIL in livestock and Foot and Mouth Disease vaccines globally and in India, with overlapping veterinary biologics portfolio.
• Bharat Biotech: Hyderabad-headquartered Indian vaccine manufacturer with overlapping human vaccine portfolio (including rabies and Hepatitis A adjacencies), competing for government immunization contracts.
• Hester Biosciences: India-based veterinary vaccine manufacturer with overlapping livestock and poultry vaccine portfolio, comparable scale and distribution through government and private channels.
• Brilliant Bio Pharma: Indian-origin FMD vaccine producer named as a key competitor with IIL in the domestic and regional livestock vaccine market.
• Boehringer Ingelheim Animal Health (Merial): Major global animal health player explicitly named alongside IIL as a key competitor in the Foot and Mouth Disease vaccine market, with broad veterinary biologics portfolio.

Broad incumbents

• Serum Institute of India: World's largest vaccine manufacturer by doses, Indian-headquartered; competes with IIL in human vaccines and government immunization program supply, though veterinary exposure is more limited.
• Elanco Animal Health: Global animal health competitor with livestock vaccine and therapeutics portfolio comparable to IIL's veterinary franchise; broader therapeutic focus and global distribution.
• GSK (GlaxoSmithKline): Global vaccine major competing with IIL in the Hepatitis A market and broader human immunization programs; broader portfolio across vaccines and pharmaceuticals.
• Sanofi: Global vaccine major competing with IIL in the Hepatitis A vaccine market, with broad human vaccine franchise and global distribution scale.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/indimmune
• LinkedInlinkedin.com/company/indian-immunologicals-limited

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Indian Immunologicals